Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Croydon, United Kingdom Clinical Trials

A listing of Croydon, United Kingdom clinical trials actively recruiting patients volunteers.

RESULTS

Found (26) clinical trials

Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer

This is an open-label, randomized, parallel group two-stage phase 1-2 study with an escalation and an expansion component. This study will evaluate an extended-release (ER) formulation of onapristone in patients with prostate cancer in which Progesterone Receptor (PR) may be contributing to tumor progression. A companion diagnostic to select patients ...

Phase

4.25 miles

Learn More »

Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase 1b: In the dose escalation portion of the study, various cohorts with escalating doses of lenalidomide may be explored, using the 3+3+3 principle for dose determination. Phase 2: This will be conducted as an international, multicenter, open-label study. Eligible subjects will receive ibrutinib, lenalidomide and rituximab.

Phase

4.25 miles

Learn More »

Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma

This is the first study of the oral formulation of BAL101553. BAL101553 will be administered once daily during each day of a 28-day treatment cycle in capsule form to adults with advanced or recurrent solid tumors or recurrent or progressive glioblastoma or high-grade glioma who have failed standard therapy, or ...

Phase

4.57 miles

Learn More »

PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer

Ovarian cancer is the fourth biggest contributor to female cancer mortality, accounting for 4% of all malignancies diagnosed in women. In the United Kingdom (UK), there are seven thousand new cases of ovarian cancer annually and four thousand two hundred deaths from the disease. The standard treatment approach currently consists ...

Phase

4.57 miles

Learn More »

p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246

The purpose of this study is to make a preliminary assessment of the efficacy of a combined APR-246 and carboplatin/PLD chemotherapy regimen, compared with carboplatin/PLD chemotherapy regimen alone, in patients with platinum sensitive recurrent high grade serous ovarian cancer (HGSOC) with mutated p53. In addition, the study aims to assess ...

Phase

4.57 miles

Learn More »

Gemcitabine Paclitaxel Ifosfamide and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors

OBJECTIVES: - To determine the maximum tolerated dose (MTD) of gemcitabine hydrochloride when administered with TIP chemotherapy comprising paclitaxel, ifosfamide, and cisplatin with growth factor support (Gem-TIP) in patients with progressive or relapsed metastatic germ cell tumors. - To compare the MTD of the Gem-TIP regimen with the MTD determined ...

Phase

4.57 miles

Learn More »

HuMax-AXL-ADC Safety Study in Patients With Solid Tumors

The trial consists of two parts; a dose escalation part (phase I, first in- human (FIH)) and an expansion part (phase IIa). The dose escalation part has two dose escalation arms: the first arm investigates a once every 3 weeks (1Q3W) dose schedule and the second one investigates a three ...

Phase

4.57 miles

Learn More »

A Study to Evaluate the Safety Tolerability Pharmacokinetics Immunogenicity and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors

This early phase, multicenter, open-label, single-arm study will evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of atezolizumab in pediatric and young adult participants with solid tumors for which prior treatment was proven to be ineffective.

Phase

4.62 miles

Learn More »

Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors

This open-label, dose-escalation study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of cobimetinib in pediatric and young adult participants with solid tumors with known or potential kinase pathway activation for which standard therapy has proven to be ineffective or intolerable or for which no curative standard-of-care ...

Phase

4.62 miles

Learn More »

Tisotumab Vedotin (HuMax -TF-ADC) Safety Study in Patients With Solid Tumors

The study is conducted in two parts. The dose escalation portion of the trial subjects are enrolled into cohorts at increasing dose levels of tisotumab vedotin (HuMax-TF-ADC) in 28 day treatment cycles. In the Cohort Expansion part of the trial, will further explore the recommended phase 2 dose of tisotumab ...

Phase

4.62 miles

Learn More »